Cargando…

An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients

BACKGROUND: In contrast to inpatient central line associated blood stream infections (CLABSIs), little attention has been devoted to preventing outpatient CLABSIs or central line associated noninfectious complications (CLANCs). Our aim was to develop and validate a novel index to comprehensively qua...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelada, Aml, Foster, Timothy, Worley, Sarah, Tang, Anne, Arakoni, Venkatraman, B Foster, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631131/
http://dx.doi.org/10.1093/ofid/ofx163.1839
_version_ 1783269376305135616
author Kelada, Aml
Foster, Timothy
Worley, Sarah
Tang, Anne
Arakoni, Venkatraman
B Foster, Charles
author_facet Kelada, Aml
Foster, Timothy
Worley, Sarah
Tang, Anne
Arakoni, Venkatraman
B Foster, Charles
author_sort Kelada, Aml
collection PubMed
description BACKGROUND: In contrast to inpatient central line associated blood stream infections (CLABSIs), little attention has been devoted to preventing outpatient CLABSIs or central line associated noninfectious complications (CLANCs). Our aim was to develop and validate a novel index to comprehensively quantify the rates of both CLABSIs and CLANCs among pediatric oncology patients. METHODS: CLABSIs were defined according to CDC/NHSN definitions. CLANCs were defined using a novel classification as noninfectious events resulting in premature removal of the line. 592 oncology patient records (< 24 years; 2006–16) were reviewed. Wilcoxon rank-sum tests were used for continuous and ordinal characteristics and Chi-square or Fisher’s exact tests for categorical characteristics. RESULTS: 656 CVCs were inserted in 368 patients, for a total of 175,941catheter days (9.6% inpatient). Events included: 108 CLABSIs (42 inpatient and 66 outpatient) and 89 CLANCs (44 inpatient and 45 outpatient). The all-harm event rate was 1.1 per 1000 CVC days; the sum of CLABSI (0.61) and CLANC (0.50) rates. Inpatient rates were: all-harm (4.9), CLABSIs (2.4), and CLANCs (2.5). Outpatient event rates were: all-harm (0.72), CLABSIs (0.45), and CLANCs (0.27). For all lines treated independently, risk ratio of an adverse event was strongly correlated with CVC type (tunneled CVCs vs ports; 11.8; <0.001), age at placement per 1 year older (0.89; <0.001), gender (females vs males; 1.6; 0.021), and tumor type (AML vs Non-AML Leukemia/Lymphoma; 4.0; <0.001). Tunneled CVCs carried greater risk for both CLABSI (10.8; <0.001) and CLANC (13.2; <0.001) than ports. CONCLUSION: We have developed an all-harm index to quantify the total harm associated with central line use. Among pediatric oncology patients with CVCs, major noninfectious complications occur at rates similar to those reported for CLABSIs. Although event rates per 1000 CVC days were lower among outpatients, the total number of infectious and noninfectious harm events was similar in the inpatient and outpatient settings. Additional quality improvement efforts are required to reduce the total harm associated with CVC use, and modifiable factors such as catheter choice could significantly impact the rate of both CLABSIs and CLANCs. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5631131
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56311312017-11-07 An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients Kelada, Aml Foster, Timothy Worley, Sarah Tang, Anne Arakoni, Venkatraman B Foster, Charles Open Forum Infect Dis Abstracts BACKGROUND: In contrast to inpatient central line associated blood stream infections (CLABSIs), little attention has been devoted to preventing outpatient CLABSIs or central line associated noninfectious complications (CLANCs). Our aim was to develop and validate a novel index to comprehensively quantify the rates of both CLABSIs and CLANCs among pediatric oncology patients. METHODS: CLABSIs were defined according to CDC/NHSN definitions. CLANCs were defined using a novel classification as noninfectious events resulting in premature removal of the line. 592 oncology patient records (< 24 years; 2006–16) were reviewed. Wilcoxon rank-sum tests were used for continuous and ordinal characteristics and Chi-square or Fisher’s exact tests for categorical characteristics. RESULTS: 656 CVCs were inserted in 368 patients, for a total of 175,941catheter days (9.6% inpatient). Events included: 108 CLABSIs (42 inpatient and 66 outpatient) and 89 CLANCs (44 inpatient and 45 outpatient). The all-harm event rate was 1.1 per 1000 CVC days; the sum of CLABSI (0.61) and CLANC (0.50) rates. Inpatient rates were: all-harm (4.9), CLABSIs (2.4), and CLANCs (2.5). Outpatient event rates were: all-harm (0.72), CLABSIs (0.45), and CLANCs (0.27). For all lines treated independently, risk ratio of an adverse event was strongly correlated with CVC type (tunneled CVCs vs ports; 11.8; <0.001), age at placement per 1 year older (0.89; <0.001), gender (females vs males; 1.6; 0.021), and tumor type (AML vs Non-AML Leukemia/Lymphoma; 4.0; <0.001). Tunneled CVCs carried greater risk for both CLABSI (10.8; <0.001) and CLANC (13.2; <0.001) than ports. CONCLUSION: We have developed an all-harm index to quantify the total harm associated with central line use. Among pediatric oncology patients with CVCs, major noninfectious complications occur at rates similar to those reported for CLABSIs. Although event rates per 1000 CVC days were lower among outpatients, the total number of infectious and noninfectious harm events was similar in the inpatient and outpatient settings. Additional quality improvement efforts are required to reduce the total harm associated with CVC use, and modifiable factors such as catheter choice could significantly impact the rate of both CLABSIs and CLANCs. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631131/ http://dx.doi.org/10.1093/ofid/ofx163.1839 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Kelada, Aml
Foster, Timothy
Worley, Sarah
Tang, Anne
Arakoni, Venkatraman
B Foster, Charles
An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients
title An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients
title_full An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients
title_fullStr An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients
title_full_unstemmed An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients
title_short An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients
title_sort all-harm index quantifying central line associated infectious and noninfectious complications among pediatric oncology patients
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631131/
http://dx.doi.org/10.1093/ofid/ofx163.1839
work_keys_str_mv AT keladaaml anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT fostertimothy anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT worleysarah anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT tanganne anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT arakonivenkatraman anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT bfostercharles anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT keladaaml allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT fostertimothy allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT worleysarah allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT tanganne allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT arakonivenkatraman allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients
AT bfostercharles allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients